Effect of supplementation in treatment of Coronary Heart Disease

The effect of Resveratrol supplement on metabolic profiles and genes expression of Sirtuin-1? TNF-a? TGF-ß? IL-1? PPAR? in diabetetic coronary artery disease patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181029041490N1

Enrollment

Registered

2018-12-05

Start date

2018-08-16

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease. Chronic ischemic heart disease, unspecified

Interventions

Intervention 1: Intervention group: Resveratrol supplements, 500mg, daily, for 4 weeks orally. Intervention 2: Control group: Placebo, daily, for 4 weeks orally.

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: patients with T2DM, aged 40-85 years old with proven 2- and 3-vessel CHD

Exclusion criteria

Exclusion criteria: Consuming resveratrol three months prior to the intervention Taking antioxidant and/or anti-inflammatory supplements such as vitamin E and vitamin C Having an acute myocardial infarction or cardiac surgery in the past three months Having renal or hepatic failure

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Calculation using HOMA formula.	—

Secondary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Gene expression of sirtuin1. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of interleukin-1(IL-1). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of tumor necrosis factor alpha (TNF-a). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of transforming growth factor beta (TGF-ß). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of peroxisome proliferator-activated receptor gamma (PPAR-?). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL-cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic	—

Measure

Time frame

Hs-CRP. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Gene expression of sirtuin1. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of interleukin-1(IL-1). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of tumor necrosis factor alpha (TNF-a). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of transforming growth factor beta (TGF-ß). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Gene expression of peroxisome proliferator-activated receptor gamma (PPAR-?). Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Real Time PCR.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Insulin. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Elisa kit.;Triglycerides. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL-cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Namazi

Kashan University of Medical Sciences

namazimajid@gmail.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026